UNSPSC 51281669: Spectinomycin hydrochloride anhydrous

This classification denotes an aminoglycoside antibiotic with the molecular formula C14H24N2O7.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 296JEI210Z, chemically known as 4h-pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, dihydrochloride, but more generally known as spectinomycin hydrochloride anhydrous, which bears US NIH Compound Identifier 3033928.

UNSPSC 51281669 Spectinomycin hydrochloride anhydrous (Commodity) appears in state and local procurement activity, but the recent opportunities tagged under this code do not align with its narrow pharmaceutical scope. The four most recent solicitations posted between January and June 2026 pursue naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, general medical and first aid supplies for fire rescue operations, and multi-source generic pharmaceuticals and OTC products through cooperative purchasing—none of which target spectinomycin hydrochloride anhydrous specifically. The issuing bodies span state health agencies (Texas HHS Commission), county health departments (Seminole County, Florida), municipal fire departments (City of Tampa), and state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). The geographic activity identified includes Florida, Texas, Minnesota, and Oregon through cooperative membership.

The mismatch between the code's nominal scope and the actual procurements suggests limited or misclassified recent activity for spectinomycin hydrochloride anhydrous itself. The representative opportunities show state and local demand for pharmaceutical supply-chain solutions, generic drugs and OTC products through authorized wholesalers, emergency medical consumables, and direct contracting with manufacturers—but none explicitly target spectinomycin. The City of Tampa's IFB 26P00145 (medical and first aid supplies, due March 13, 2026, estimated $700,000) and the Minnesota MMCAP RFP S1070000015802 (generic multi-source pharmaceuticals and OTC products, due March 26, 2026) represent the broader pharmaceutical procurement environment, yet neither names spectinomycin. This code warrants further research to determine whether state and local procurement of spectinomycin hydrochloride anhydrous is genuinely active or whether the UNSPSC classification is a data-entry artifact masking opportunity elsewhere.